EU concludes major free trade agreement with Mercosur countries
European pharma industry acknowledges the progress made, particularly with partial tariff reductions, but said further provisions could have been achieved.
List view / Grid view
European pharma industry acknowledges the progress made, particularly with partial tariff reductions, but said further provisions could have been achieved.
The European Commission’s new framework aims to improve safety assessment of chemicals to better protect human health and the environment.
And as the Critical Medicines Act advances, so too does the Biotech Act, with the moves attracting mixed support from the region’s pharma industry.
The monoclonal antibody becomes the first neonatal Fc receptor (FcRn) blocker to be approved in Europe for the condition.
Changes proposed in the EU body’s regulatory framework aim to create a competitive and sustainable European bioeconomy.
European approval of Sanofi and Regeneron’s monoclonal antibody provides eligible urticaria patients with a new first-line targeted treatment option.
Authorisation of the biosimilar Gobivaz provides a substitute biologic medicine to Simponi for individuals with immune-mediated diseases.
Oral small molecule treatment Brinsupri (brensocatib) could become a new standard of care for patients with the progressive lung disease.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
The European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.
Marking the first step in the negotiation process, this deal establishes key parameters of the final political agreement on trade and tariffs between the EU and US.
The EU authorisation offers a new treatment option for acromegaly, providing effective disease control and enabling convenient self-administration.